MorphoSys AG (ETR:MOR) Given a €77.00 Price Target by Independent Research GmbH Analysts
MOR has been the subject of several other reports. Berenberg Bank set a €68.00 ($80.00) price target on MorphoSys AG and gave the company a buy rating in a report on Thursday, May 25th. Commerzbank Ag set a €76.00 ($89.41) price target on MorphoSys AG and gave the company a buy rating in a report on Tuesday, June 6th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price target on MorphoSys AG and gave the company a neutral rating in a report on Friday. HSBC Holdings plc set a €59.00 ($69.41) price target on MorphoSys AG and gave the company a neutral rating in a report on Friday, July 14th. Finally, Deutsche Bank AG set a €90.00 ($105.88) price target on MorphoSys AG and gave the company a buy rating in a report on Monday. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of €69.57 ($81.85).
MorphoSys AG (ETR MOR) traded up 0.496% during mid-day trading on Monday, hitting €59.511. 1,469 shares of the stock traded hands. MorphoSys AG has a 52-week low of €35.72 and a 52-week high of €70.90. The firm’s 50-day moving average is €62.74 and its 200 day moving average is €57.44. The firm’s market cap is €1.71 billion.
WARNING: “MorphoSys AG (ETR:MOR) Given a €77.00 Price Target by Independent Research GmbH Analysts” was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/08/morphosys-ag-etrmor-given-a-77-00-price-target-by-independent-research-gmbh-analysts-2.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.